Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227)

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 257-271

  Seiwert, Scott D ^a   Kossen, Karl ^a   Pan, Lin ^a   Liu, Jyanwei ^a   Buckman, Brad O ^a  

^a InterMune Inc   (United States)

Author keywords

Biochemical characteristics, danoprevir and NS3 4A, in two step binding mechanism; HCV NS3 4A protease inhibitor danoprevir NS3 4A protease inhibitors (PIs), antiviral activity; Virological response, promoted by danoprevir and peginterferon 2a and ribavirin

Indexed keywords

EID: 84886064859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch18     Document Type: Chapter

References (78)

1. Shepard, C.W., et al. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5, 558-567.
2. NIH consensus statement on management of hepatitis C: 2002. NIH Consens. State. Sci. State. 2002, 19, 1-46.
3. Manns, M. P., et al. Peginterferon alfa-2b plus ribavirin comparedwith interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358, 958-965.
4. Fried, M. W., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
5. Lemon, S. M., et al. "Strong reasons make strong actions": the antiviral efficacy of NS3/4A protease inhibitors. Hepatology 2005, 41, 671-674.
6. Neukam, K., et al. A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin. Pharmacother. 2009, 10, 417-433.
7. Pawlotsky, J. M. Hepatitis C: it's a long way to new therapy, it's a long way to go. Gastroenterology 2004, 127, 1629-1632.
8. Gale, M., Jr.; Foy, E. M. Evasion of intracellular host defense by hepatitis C virus. Nature 2005, 436, 939-945.
9. Thimme, R., et al. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 2006, 69, 129-141.
10. Lamarre, D., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426, 186-189.
11. Hinrichsen, H., et al. Short-term antiviral efficacy of BILN 2061, a hepatitisCvirus serine protease inhibitor, in hepatitisC genotype 1 patients. Gastroenterology 2004, 127, 1347-1355.
12. Reiser, M., et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005, 41, 832-835.
13. Forestier, N., et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patientswith theNS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology 2008, 48, 1132A.
14. Manns, M., et al. Safety and antiviral activity of TMC436350 in treatment-naive genotype 1 HCV-infected patients. Hepatology 2008, 48, 1023A.
15. Lawitz, E., et al. Safety, Tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. Hepatology 2008, 48, 403A.
16. Manns,M. P., et al. Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, on combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P + R treatment-experienced patients with chronic hepatitis C genotype 1 infection. Hepatology 2008, 48, 1151A-1152A.
17. Reesink, H., et al. Safety and antiviral activity of S administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J. Hepatol. 2009, 50(Suppl. 1), S35.
18. Forestier, N., et al. Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV). J. Hepatol. 2009, 50, S35.
19. Manns, M. P., et al. MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. J. Hepatol. 2009, 50(Suppl. 1), S384.
20. Mederacke, I., et al. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment ofHCVinfection. Curr. Opin. Invest. Drugs 2009, 10, 181-189.
21. Njoroge, F. G., et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res. 2008, 41, 50-59.
22. Perni, R. B., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899-909.
23. McHutchison, J. G., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360, 1827-1838.
24. Hezode, C., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360, 1839-1850.
25. Kwo, P., et al. Final results: SVR 24 NS3 protease inhibitor boceprevir plus pegIFN alpha-2b/ribavirinHCV1 in treatment naive patients. J. Hepatol. 2009, 50(Suppl. 1), S4.
26. Evans, M.; Rees, A. The myotoxicity of statins. Curr. Opin. Lipidol. 2002, 13, 415-420.
27. Evans, M.; Rees,A. Effects ofHMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf. 2002, 25, 649-663.
28. Igel, M., et al. Pharmacology of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J. Clin. Pharmacol. 2002, 42, 835-845.
29. Johansson, A., et al. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. Bioorg. Med. Chem. 2003, 11, 2551-2568.
30. Rieger,R.A., et al. Pharmacokinetic analysis and liver concentrations of a series of macrocyclic peptidomimetic inhibitors of HCV NS3/4A protease: identification of ITMN-191, a potent NS3/4A protease inhibitor with high liver exposure across multiple species. Gastroenterology 2006, 130, A-835.
31. Rajagopalan, P. T. R., et al. Characterization of HCV NA3/4a protease inhibition by ITMN 191 reveals picomolar potency and slowdissociation: implications for the use of ITMN191 in chronic HCV treatment. Gastroenterology 2007, 132, A-782.
32. Lin, T., et al. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6. Hepatology 2008, 48, 1166A.
33. Condroski, K., et al. Structure-based design of novel isoindolene inhibitors of HCV NS3/4A protease and binding mode analysis of ITMN 191 by x-ray crystallography. Gastroenterology 2006, 130, A835.
34. Lewandowicz, A., et al. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem. 2003, 278, 31465-31468.
35. Tian, G. In vivo time-dependent inhibition of human steroid 5 alpha-reductase by finasteride. J. Pharm. Sci. 1996, 85, 106-111.
36. Bull, H. G., et al. Mechanism-based inhibition of human steroid 5a-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 1996, 118, 2359-2365.
37. Zhong, J., et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 9294-9299.
38. Neumann, A. U., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282, 103-107.
39. Tanaka, J., et al. Early dynamics of hepatitis C virus in the circulation of chimpanzees with experimental infection. Intervirology 2005, 48, 120-123.
40. Dierynck, I., et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. Virol. 2007, 81, 13845-13851.
41. Foster, G. R., et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J. Hepatol. 2009, 50(Suppl. 1), S22.
42. Hoofnagle, J. H. A step forward in therapy for hepatitis C. N. Engl. J. Med. 2009, 360, 1899-1901.
43. Thompson, A., et al. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J. Hepatol. 2009, 50, 184-194.
44. Chen, K. X., et al. Second generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protein. J. Am. Chem. Soc. 2009, 52, 1370-1379.
45. Seiwert, S. D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 2008, 52, 4432-4441.
46. Perni, R. B., et al. VX-950: The discovery of an inhibitor of the hepatitis C NS3/4A protease and a potential hepatitis C virus therapeutic. Hepatology 2003, 38, 130A.
47. Benhamou,Y., et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4HCV patients. J. Hepatol. 2009, 50(Suppl. 1), S6.
48. Bierman,W. F., et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009, 23, 279-291.
49. Sarrazin, C., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132, 1767-1777.
50. Kukolj, G., et al. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol. 2009, 50, S347.
51. Sarrazin, C., et al. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combinationwith peginterferon alfa-2a/ribavirin. J.Hepatol. 2009, 50(Suppl, 1), S345.
52. Manns,M., et al. Opera-1 Trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J. Hepatol. 2009, 50(Suppl. 1), S7.
53. Forestier, N., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007, 46, 640-648.
54. Kieffer, T. L., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46, 631-639.
55. Nijhuis, M., et al. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 2009, 189, 299-320.
56. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 2007, 6, 1001-1018.
57. De Clercq, E.Anti-HIV drugs: 25 compounds approvedwithin 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33, 307-320.
58. Reesink, H.W., et al. Rapid decline of viral RNAin hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131, 997-1002.
59. Le Pogam, S., et al. No evidence of R7128 drug resistance after up to 4 weeks treatment of genotype 1, 2, and 3 hepatitis C virus infected individuals. J. Hepatol. 2009, 50(Suppl. 1), S348.
60. Le Pogam, S., et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 2008, 61, 1205-1216.
61. McCown, M. F., et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52, 1604-1612.
62. Lalezari, J., et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor, R7128, in combination with peg-IFN a-2a and ribavirin. J. Hepatol. 2008, 48, S29.
63. Gane, E. J., et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Hepatology 2008, 48.
64. Pockros, P. J., et al. Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a 940KD), with or without ribavirin: interim analysis of results of phase 2A study. Hepatology 2007, 46, 311A.
65. Tan, H., et al. Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Hepatology 2008, 48, 1153A.
66. Bradford, W. Z., et al. A Phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects. Hepatology 2008, 48, 1146A.
67. Rubino, C., et al. Pharmacokinetic-pharmacodynamic (PKPD) relationships for ITMN-191 in a phase 1 multiple ascending dose trial in patients with genotype 1 chronic hepatitis C (CHC) infection. Hepatology 2008, 48, 1140A.
68. Susser, S., et al. Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long term follow-up in patients treated with boceprevir. J. Hepatol. 2009, 50, S7.
69. Lu, L., et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 2004, 48, 2260-2266.
70. Zhou, Y., et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 2007, 282, 22619-22628.
71. McCown, M. F., et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 2009, 53, 2129-2132.
72. He, Y., et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitisCvirus (HCV)NS3 protease mutants in theHCVgenotype 1b replicon system. Antimicrob. Agents Chemother. 2008, 52, 1101-1110.
73. Maschera, B., et al. Human immunodeficiency virus: mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 1996, 271, 33231-33235.
74. Shuman, C. F., et al. Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res. 2003, 58, 235-242.
75. Reddy, R., et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007, 46, 862A-863A.
76. Brown, N. A. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors: I. Nucleoside analogues. Expert Opin. Invest. Drugs 2009, 18, 709-725.
77. Gane, E. J., et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J. Hepatol. 2009, 50(Suppl. 1), S380.
78. Lawitz, E., et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 2008, 49, 163-169.